New combo therapy aims to shrink ovarian tumors before surgery
NCT ID NCT07432594
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding an experimental immunotherapy (Aitua Combination Antibody) to standard chemotherapy can help shrink advanced ovarian cancer more effectively before surgery. About 82 women with stage IIIC-IV high-grade serous ovarian cancer who cannot have optimal surgery upfront will receive either chemo alone or chemo plus the immunotherapy for 3 cycles, then undergo surgery. The main goal is to see if more tumors can be completely removed during surgery with the combination.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a custom vaccine train the body to fight ovarian cancer?
- Can a daily pill keep BRCA-Linked ovarian cancer at bay?
- New drug cocktail aims to shrink recurrent ovarian tumors
- New drug combo aims to stall ovarian cancer in patients without common DNA repair flaw
- Real-World check: can a targeted ovarian cancer drug deliver outside clinical trials?
- Immune cells Re-Trained to fight Drug-Resistant ovarian cancer